Pulse Medical Secures Tens of Millions RMB Series A Funding Led by Chende Capital

Pencil News, June 5 – Recently, the tech-innovation enterprise Pulse Medical completed a Series A financing round worth tens of millions of RMB, with Chende Capital as the investor. The proceeds from this round will be used to advance the clinical trials of the Leftear® Left Atrial Appendage Occluder and accelerate the R&D progress of multiple product pipelines under development.

It is reported that Pulse Medical previously received angel-round investment from Zhuhai High-Tech Investment and Chende Capital.

“Pulse Medical,” established in 2014, is a technology-driven enterprise specializing in the research and development, manufacturing, and sales of high-end cardiovascular medical devices and consumables. “Pulse Medical” is committed to building a comprehensive cardiovascular healthcare product industry chain encompassing “prevention + diagnosis + treatment + rehabilitation.” Its passive products include the Leftear® Left Atrial Appendage Occluder, the C-reducer™ Left Ventricular Isolation System (volume reduction umbrella), and disposable balloon inflation pressure pumps, among others. Its active products include wearable ECG monitoring devices, extracorporeal shockwave therapy instruments, high-definition whole-body imaging detectors, and dynamic cardiac imaging detectors, among others.

Chende Capital highly affirms Pulse Medical’s R&D and innovation capabilities and remains bullish on the future development trends of the structural heart disease diagnosis and treatment market. Structural heart disease has become a hot investment sector in recent years, with broad market prospects. With its strong R&D capabilities and clinical resources, Pulse Medical is expected to achieve accelerated growth following this round of financing.